Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 4
2004 5
2005 10
2006 13
2007 16
2008 11
2009 11
2010 16
2011 16
2012 15
2013 18
2014 17
2015 15
2016 21
2017 23
2018 22
2019 28
2020 35
2021 24
2022 29
2023 28
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

342 results

Results by year

Filters applied: . Clear all
Page 1
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.
Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, Lenihan D, Onofrei C, Shannon V, Sharma R, Silk AW, Skondra D, Suarez-Almazor ME, Wang Y, Wiley K, Kaufman HL, Ernstoff MS; Society for Immunotherapy of Cancer Toxicity Management Working Group. Puzanov I, et al. J Immunother Cancer. 2017 Nov 21;5(1):95. doi: 10.1186/s40425-017-0300-z. J Immunother Cancer. 2017. PMID: 29162153 Free PMC article.
Dual inhibition of TGF-β and PD-L1: a novel approach to cancer treatment.
Gulley JL, Schlom J, Barcellos-Hoff MH, Wang XJ, Seoane J, Audhuy F, Lan Y, Dussault I, Moustakas A. Gulley JL, et al. Mol Oncol. 2022 Jun;16(11):2117-2134. doi: 10.1002/1878-0261.13146. Epub 2022 Jan 4. Mol Oncol. 2022. PMID: 34854206 Free PMC article. Review.
In Reply.
Gubbi S, Cordes LM, Klubo-Gwiezdzinska J, Madan RA, Nieman LK, Gulley JL, Del Rivero J. Gubbi S, et al. Among authors: gulley jl. Oncologist. 2021 Jan;26(1):e192-e193. doi: 10.1002/onco.13589. Epub 2020 Nov 23. Oncologist. 2021. PMID: 33150998 Free PMC article.
Adaptive Immunity in Genitourinary Cancers.
Koti M, Bivalacqua T, Black PC, Cathomen T, Galsky MD, Gulley JL, Ingersoll MA, Kamat AM, Kassouf W, Siemens DR, Gao J. Koti M, et al. Among authors: gulley jl. Eur Urol Oncol. 2023 Jun;6(3):263-272. doi: 10.1016/j.euo.2023.03.002. Epub 2023 Apr 15. Eur Urol Oncol. 2023. PMID: 37069029 Free article. Review.
Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-β blockade in HPV-unrelated head and neck cancer.
Redman JM, Friedman J, Robbins Y, Sievers C, Yang X, Lassoued W, Sinkoe A, Papanicolau-Sengos A, Lee CC, Marte JL, Turkbey E, Mydlarz W, Joshi A, London NR Jr, Pierce M, Taylor R, Hong S, Nguyen A, Soon-Shiong P, Schlom J, Gulley JL, Allen CT. Redman JM, et al. Among authors: gulley jl. J Clin Invest. 2022 Sep 15;132(18):e161400. doi: 10.1172/JCI161400. J Clin Invest. 2022. PMID: 35727629 Free PMC article. Clinical Trial.
HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study.
Naranbhai V, Viard M, Dean M, Groha S, Braun DA, Labaki C, Shukla SA, Yuki Y, Shah P, Chin K, Wind-Rotolo M, Mu XJ, Robbins PB, Gusev A, Choueiri TK, Gulley JL, Carrington M. Naranbhai V, et al. Among authors: gulley jl. Lancet Oncol. 2022 Jan;23(1):172-184. doi: 10.1016/S1470-2045(21)00582-9. Epub 2021 Dec 9. Lancet Oncol. 2022. PMID: 34895481 Free PMC article.
Cooperative Armoring of CAR and TCR T Cells by T Cell-Restricted IL15 and IL21 Universally Enhances Solid Tumor Efficacy.
Nguyen R, Doubrovina E, Mousset CM, Jin BY, Okada R, Zhang X, Clavel A, Reyes-Gonzalez JM, Dyomin V, Diaz L, Zhang L, Abbas S, Sun M, Hsieh CM, Ho M, Shern JF, Gulley JL, Hinrichs CS. Nguyen R, et al. Among authors: gulley jl. Clin Cancer Res. 2024 Apr 15;30(8):1555-1566. doi: 10.1158/1078-0432.CCR-23-1872. Clin Cancer Res. 2024. PMID: 37910044
Vaccinating against cancer: getting to prime time.
Chang R, Gulley JL, Fong L. Chang R, et al. Among authors: gulley jl. J Immunother Cancer. 2023 Jun;11(6):e006628. doi: 10.1136/jitc-2022-006628. J Immunother Cancer. 2023. PMID: 37286302 Free PMC article. Review.
Therapeutic cancer vaccines.
Schlom J, Hodge JW, Palena C, Tsang KY, Jochems C, Greiner JW, Farsaci B, Madan RA, Heery CR, Gulley JL. Schlom J, et al. Among authors: gulley jl. Adv Cancer Res. 2014;121:67-124. doi: 10.1016/B978-0-12-800249-0.00002-0. Adv Cancer Res. 2014. PMID: 24889529 Free PMC article. Review.
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce.
Kluger HM, Tawbi HA, Ascierto ML, Bowden M, Callahan MK, Cha E, Chen HX, Drake CG, Feltquate DM, Ferris RL, Gulley JL, Gupta S, Humphrey RW, LaVallee TM, Le DT, Hubbard-Lucey VM, Papadimitrakopoulou VA, Postow MA, Rubin EH, Sharon E, Taube JM, Topalian SL, Zappasodi R, Sznol M, Sullivan RJ. Kluger HM, et al. Among authors: gulley jl. J Immunother Cancer. 2020 Mar;8(1):e000398. doi: 10.1136/jitc-2019-000398. J Immunother Cancer. 2020. PMID: 32238470 Free PMC article.
342 results